A growing body of neurological research, led by a significant study from the University of California, San Francisco (UCSF), suggests that the current medical standards for "normal" vitamin B12 levels may be insufficient for maintaining optimal brain health in older populations. While vitamin B12 is traditionally celebrated for its role in DNA synthesis, the production of red blood cells, and the maintenance of nerve tissue, the new findings indicate that even levels falling within the accepted laboratory range could be associated with subtle yet measurable neurological impairment. The study raises critical questions about whether the current thresholds for B12 deficiency are too low to capture the early stages of cognitive decline and brain injury.
The UCSF-led research, published in the peer-reviewed journal Annals of Neurology, focused on a cohort of healthy older adults who did not display symptoms of dementia or mild cognitive impairment. Despite their apparent health, those with lower levels of active vitamin B12—even within the standard clinical "normal" range—exhibited slower cognitive processing and visible damage to the brain’s white matter. This discovery suggests a "silent" phase of B12 insufficiency where the brain experiences strain long before clinical symptoms of deficiency, such as anemia or severe memory loss, become apparent.
Redefining the Threshold of Deficiency
The research team, spearheaded by senior author Ari J. Green, MD, of the UCSF Departments of Neurology and Ophthalmology and the Weill Institute for Neurosciences, argued that the current clinical guidelines for B12 may have a significant blind spot. Historically, vitamin B12 deficiency has been defined primarily by the presence of macrocytic anemia, a condition where the body produces abnormally large red blood cells. However, the neurological system may be more sensitive to B12 fluctuations than the hematological system.
"Previous studies that defined healthy amounts of B12 may have missed subtle functional manifestations of high or low levels that can affect people without causing overt symptoms," Dr. Green noted. He emphasized that the medical community might need to revisit the definition of deficiency to incorporate functional biomarkers—indicators of how the vitamin is actually being used by the body—rather than relying solely on total serum levels. Such a shift could facilitate earlier interventions and potentially prevent or delay the onset of age-related cognitive decline.
The BrANCH Study: Methodology and Findings
To investigate the relationship between B12 and brain health, researchers analyzed data from 231 healthy participants enrolled in the Brain Aging Network for Cognitive Health (BrANCH) study at UCSF. The participant pool had an average age of 71, providing a representative look at the demographic most at risk for age-related neurological changes. Crucially, none of the participants met the criteria for dementia at the start of the study.
The methodology of the study was distinct in its focus on "active" vitamin B12, also known as holotranscobalamin. While standard blood tests measure total B12, much of that total is bound to proteins that make it unavailable for cellular use. Active B12 represents the fraction of the vitamin that can actually be utilized by the nervous system. The average total B12 level among participants was 414.8 pmol/L, which is significantly higher than the U.S. clinical cutoff for deficiency, typically set at 148 pmol/L.
Despite these seemingly healthy numbers, the data revealed a troubling correlation. After the researchers adjusted for variables such as age, sex, education level, and cardiovascular risk factors, they found that participants with lower active B12 levels performed significantly worse on tests measuring cognitive processing speed. This effect was notably more pronounced as the age of the participants increased. Furthermore, these individuals showed delayed responses to visual stimuli, a hallmark of reduced brain signaling efficiency.
MRI Evidence of White Matter Injury
Perhaps the most striking evidence came from magnetic resonance imaging (MRI) scans. The researchers discovered that participants with lower active B12 levels possessed a higher volume of white matter hyperintensities, often referred to as white matter lesions. White matter is the "cabling" of the brain, consisting of nerve fibers wrapped in myelin that allow different regions of the brain to communicate.
Lesions in the white matter are considered markers of small vessel disease and have been consistently linked to an increased risk of stroke, dementia, and general cognitive slowing. Finding these lesions in individuals who are technically "B12 sufficient" by current standards suggests that the brain may be suffering from a lack of the vitamin even when the rest of the body appears to have enough. The presence of these lesions provides a structural basis for the slower processing speeds observed in the cognitive tests.
The Biological Vulnerability of Older Adults
The focus on older adults is particularly relevant due to the biological changes that occur with aging. The absorption of vitamin B12 is a complex process requiring stomach acid and a protein called intrinsic factor. As people age, the production of stomach acid often declines (a condition known as atrophic gastritis), making it harder to extract B12 from animal-based foods like meat, eggs, and dairy.
Furthermore, older adults are more likely to take medications that interfere with B12 absorption. Common culprits include proton pump inhibitors (PPIs) used for acid reflux and metformin, a widely prescribed medication for Type 2 diabetes. These factors, combined with the UCSF findings, suggest that "low-normal" B12 levels may be a widespread but under-recognized contributor to the cognitive challenges faced by the elderly.
Co-first author Alexandra Beaudry-Richard, MSc, who is pursuing her doctorate at UCSF and the University of Ottawa, highlighted the potential scale of this issue. She noted that these levels could "impact cognition to a greater extent than what we previously thought, and may affect a much larger proportion of the population than we realize." Beaudry-Richard advocated for clinicians to consider B12 supplementation in older patients presenting with neurological symptoms, even if their laboratory results fall within the "normal" range.
Contemporary Research and the 2025 Context
The UCSF study does not exist in a vacuum. Several high-level reviews and studies published in 2025 have added layers of complexity to the B12 discussion. A 2025 comprehensive review reaffirmed that B12 deficiency remains one of the few "modifiable" risk factors for cognitive decline. Unlike genetic predispositions, B12 status is something that can be changed through diet or supplementation, making it a high-priority target for public health initiatives.
However, other recent data suggests that B12 is not a "magic bullet" for everyone. A 2025 systematic review and meta-analysis of randomized controlled trials found that while supplementation with B vitamins (including B6, B9, and B12) did provide a benefit to global cognitive function in older adults, the effect size was relatively small. This suggests that while B12 is essential for maintaining brain health, simply loading the general population with supplements may not lead to dramatic improvements in those who are already truly sufficient.
Additionally, a 2025 study using Mendelian randomization—a method that uses genetic variants to simulate randomized trials—found no clear evidence that genetically higher levels of total serum B12 protect the general population from psychiatric or cognitive disorders. However, the authors of that study pointed out a limitation that aligns with the UCSF findings: their analysis relied on total serum B12. They acknowledged that measuring "active" B12 or functional biomarkers might have yielded different results, reinforcing the idea that total B12 is an imperfect metric for neurological health.
Clinical Implications and Future Directions
The implications of this research for clinical practice are significant. If the current thresholds are indeed too "blunt" for brain health, the medical community may need to adopt a more nuanced approach to screening. This could include:
- Prioritizing Active B12 Testing: Moving away from total B12 tests in favor of holotranscobalamin (active B12) or methylmalonic acid (MMA) tests, which better reflect cellular B12 status.
- Personalized Thresholds: Recognizing that "normal" for a 20-year-old may not be "optimal" for a 75-year-old.
- Symptom-Based Intervention: Treating patients based on neurological symptoms (like memory lapses or balance issues) even when blood work appears borderline.
The UCSF study was co-authored by Ahmed Abdelhak, MD, PhD, and received support from the Westridge Foundation and the Canadian Institutes of Health and Research. While the authors emphasize that their findings do not prove a direct cause-and-effect relationship, the correlation between lower B12 and brain injury is strong enough to warrant a re-evaluation of how we protect the aging brain.
As the global population continues to age, the search for preventable causes of dementia becomes increasingly urgent. Vitamin B12, a well-understood and inexpensive nutrient, represents a promising frontier in this effort. While more research is needed to determine the exact "optimal" level of B12 for the brain, the UCSF study serves as a vital reminder that in the realm of neurology, "normal" is not always synonymous with "healthy." For many older adults, the difference between a normal lab result and an optimal one could be the key to maintaining cognitive vitality in their later years.
